The Mater Misericordiae University Hospital is a major teaching hospital, based at Eccles Street, Phibsborough, on the northside of Dublin, Ireland. It is managed by Ireland East Hospital Group.

During the past decade, Mater Misericordiae University Hospital conducted 82 clinical trials. In the 10-year time frame, 82 clinical trials started and 42 clinical trials were completed, i.e. on average, 51.2% percent of trials that started reached the finish line to date. In the past 5 years, 38 clinical trials started and 28 clinical trials were completed. i.e. 73.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Mater Misericordiae University Hospital" #1 sponsor was "Cancer Trials Ireland" with 22 trials, followed by "University College Dublin" with 12 trials sponsored, "Mater Misericordiae University Hospital" with 8 trials sponsored, "Pfizer" with 7 trials sponsored and "Boehringer Ingelheim" with 7 trials sponsored. Other sponsors include 99 different institutions and companies that sponsored additional 77 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Mater Misericordiae University Hospital" #1 collaborator was "Mater Misericordiae University Hospital" with 7 trials as a collaborator, "Cancer Trials Ireland" with 5 trials as a collaborator, "Eli Lilly and Company" with 4 trials as a collaborator, "Health Research Board, Ireland" with 4 trials as a collaborator and "Merck Sharp & Dohme LLC" with 4 trials as a collaborator. Other collaborators include 132 different institutions and companies that were collaborators in the rest 114 trials.

According to Clinical.Site data, the most researched conditions in "Mater Misericordiae University Hospital" are "Breast Cancer" (9 trials), "Prostate Cancer" (8 trials), "Pulmonary Arterial Hypertension" (7 trials), "Breast Neoplasms" (5 trials) and "Colorectal Cancer" (5 trials). Many other conditions were trialed in "Mater Misericordiae University Hospital" in a lesser frequency.

Most popular intervention types in "Mater Misericordiae University Hospital" are "Drug" (108 trials), "Other" (20 trials), "Device" (15 trials), "Biological" (10 trials) and "Procedure" (10 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (17 trials), "Rituximab" (6 trials), "Bendamustine" (5 trials), "Cyclophosphamide" (5 trials) and "Dexamethasone" (5 trials). Other intervention names were less common.

The vast majority of trials in "Mater Misericordiae University Hospital" are 115 trials for "All" genders, 30 trials for "Female" genders and 14 trials for "Male" genders.

Currently, there are 56 active trials in "Mater Misericordiae University Hospital". 2 are not yet recruiting, 24 are recruiting, 29 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 81 completed trials in Mater Misericordiae University Hospital, undefined suspended trials, and 13 terminated clinical trials to date.

Out of the total trials that were conducted in Mater Misericordiae University Hospital, 3 "Phase 1" clinical trials were conducted, 32 "Phase 2" clinical trials and 69 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 10 trials, and there were also 20 trials that are defined as “Not Applicable".

Mater Misericordiae University Hospital has several departments that took part in Clinical trials: "Mater Misericordiae Uni Hospital; Oncology" - 8 trials, "Mater Misericordiae University Hospital, Institute for Cancer Research" - 2 trials, "Pharmacy Department" - 2 trials, "Mater Misericordiae Hospital, Department of Clinical Chemistry and Clinical Haematology" - 2 trials